Related Experiment Videos
Microencapsulated mitomycin C in transcatheter embolization of dog kidney
Abstract:
Microencapsulated mitomycin C (MMC) was utilized for arterial embolization of dog kidneys. Renal damage was evaluated by angiographic and pathologic examinations. The most extensive embolic necrosis was associated with the use of microencapsulated MMC compared to blank microcapsules, nonencapsulated MMC, and a combination of both. Arterial infusion of microencapsulated MMC kept the concentration of MMC low in the circulating blood and sustained the biological potential of MMC in the kidney for prolonged periods of time as compared with nonencapsulated MMC. Transcatheter infusion of microencapsulated MMC could be clinically applied to the therapeutic arterial embolization of the tumor-supplying vessels together with regional anticancer chemotherapy.
Insights
Microencapsulated mitomycin C (MMC) effectively induced embolic necrosis in dog kidneys. This targeted delivery method reduced circulating drug levels and prolonged therapeutic effects for potential cancer chemotherapy.
Area of Science:
- Interventional Radiology
- Oncology
- Nephrology
Background:
- Arterial embolization is a key treatment for renal tumors.
- Mitomycin C (MMC) is an effective chemotherapeutic agent.
- Improving MMC delivery and efficacy is crucial for better patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of microencapsulated mitomycin C (MMC) for arterial embolization in canine kidneys.
- To compare the renal damage and drug delivery characteristics of microencapsulated MMC versus nonencapsulated MMC.
- To assess the potential clinical application of microencapsulated MMC in transcatheter arterial embolization for cancer therapy.
Main Methods:
- Microencapsulated MMC was administered via arterial embolization in dog kidneys.
- Renal damage was assessed using both angiographic and pathological examinations.
- Drug concentration in circulating blood and sustained biological activity in the kidney were measured.
Main Results:
- Microencapsulated MMC induced the most extensive embolic necrosis compared to controls.
- Arterial infusion of microencapsulated MMC maintained low circulating blood concentrations.
- Sustained biological activity of MMC in the kidney was observed with microencapsulation.
Conclusions:
- Microencapsulated MMC demonstrates superior efficacy in inducing embolic necrosis in renal arteries.
- This delivery system offers prolonged therapeutic effect and reduced systemic exposure.
- Transcatheter infusion of microencapsulated MMC holds promise for clinical application in tumor embolization and regional chemotherapy.